KRAS and lung carcinoma: In the KRAS G12C-mutated H358 lung cancer cell line, LY3537982 exhibited significantly lower IC50 values for the inhibition of GTP-bound KRAS and phosphorylated ERK than the other two KRAS G12C inhibitors, underscoring its potent tumor growth inhibition effect (78).